抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 2293人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852631, encodeId=4c4618526316e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=RET抑制剂TPX-0046治疗肿瘤，I/II期SWORD-1期研究已取得初步临床数据, objectType=article, longId=209638, objectId=e44b2096389c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44b2096389c, replyNumber=0, likeNumber=85, createdTime=2021-12-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44b2096389c, moduleTitle=RET抑制剂TPX-0046治疗肿瘤，I/II期SWORD-1期研究已取得初步临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e44b2096389c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852656, encodeId=ae3018526568a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性, objectType=article, longId=211247, objectId=676f21124ed8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676f21124ed8, replyNumber=0, likeNumber=69, createdTime=2021-11-01, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676f21124ed8, moduleTitle=J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=676f21124ed8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852680, encodeId=fe251852680a8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Nat Commun：JAK抑制剂托法替尼治疗系统性红斑狼疮, objectType=article, longId=212645, objectId=fd3221264551, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd3221264551, replyNumber=0, likeNumber=73, createdTime=2021-08-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd3221264551, moduleTitle=Nat Commun：JAK抑制剂托法替尼治疗系统性红斑狼疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd3221264551)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852783, encodeId=9d251852e83bb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet Oncol：IDH2抑制剂Enasidenib联合阿扎胞苷治疗IDH2突变型急性髓系白血病的疗效和安全性, objectType=article, longId=218905, objectId=80032189050a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80032189050a, replyNumber=0, likeNumber=76, createdTime=2021-10-30, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80032189050a, moduleTitle=Lancet Oncol：IDH2抑制剂Enasidenib联合阿扎胞苷治疗IDH2突变型急性髓系白血病的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80032189050a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852728, encodeId=3ae91852e2851, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病, objectType=article, longId=215519, objectId=1da5215519ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da5215519ba, replyNumber=0, likeNumber=74, createdTime=2021-09-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da5215519ba, moduleTitle=SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da5215519ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852850, encodeId=ddc21852850fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BMJ子刊：SGLT-2抑制剂会造成肾损伤吗？这项2万多人的队列研究告诉你答案！, objectType=article, longId=292226, objectId=5d56292226bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d56292226bc, replyNumber=0, likeNumber=63, createdTime=2022-04-25, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d56292226bc, moduleTitle=BMJ子刊：SGLT-2抑制剂会造成肾损伤吗？这项2万多人的队列研究告诉你答案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d56292226bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852648, encodeId=daeb1852648a8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后, objectType=article, longId=210997, objectId=424321099e06, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=424321099e06, replyNumber=0, likeNumber=69, createdTime=2022-01-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=424321099e06, moduleTitle=Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=424321099e06)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852593, encodeId=b2781852593ad, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Oncol：新型PD-L1抑制剂Toripalimab可安全有效地治疗化疗难治性转移性鼻咽癌, objectType=article, longId=206332, objectId=f55120633209, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f55120633209, replyNumber=0, likeNumber=75, createdTime=2021-12-31, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f55120633209, moduleTitle=J Clin Oncol：新型PD-L1抑制剂Toripalimab可安全有效地治疗化疗难治性转移性鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f55120633209)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852707, encodeId=637f1852e0712, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Br J Cancer：质子泵抑制剂PPI的使用影响结直肠癌患者的生存率, objectType=article, longId=214207, objectId=7a5221420e49, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5221420e49, replyNumber=0, likeNumber=59, createdTime=2021-08-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5221420e49, moduleTitle=Br J Cancer：质子泵抑制剂PPI的使用影响结直肠癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5221420e49)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852629, encodeId=84f61852629a1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元, objectType=article, longId=209533, objectId=155e209533de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=155e209533de, replyNumber=0, likeNumber=72, createdTime=2021-07-30, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=155e209533de, moduleTitle=复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=155e209533de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852746, encodeId=b89f1852e46e9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ESMO Open：免疫检查点抑制剂相关的心血管不良事件的真实临床数据, objectType=article, longId=216690, objectId=9b99216690e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b99216690e2, replyNumber=0, likeNumber=50, createdTime=2021-12-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b99216690e2, moduleTitle=ESMO Open：免疫检查点抑制剂相关的心血管不良事件的真实临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b99216690e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852655, encodeId=4c4f185265592, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验, objectType=article, longId=211171, objectId=30eb2111e1ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30eb2111e1ef, replyNumber=0, likeNumber=65, createdTime=2021-07-14, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30eb2111e1ef, moduleTitle=JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30eb2111e1ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852694, encodeId=ae5518526949c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=NEJM：谷氨酰胺转胺酶2抑制剂治疗乳糜泻概念验证研究获得成功, objectType=article, longId=213720, objectId=c4b0213e20fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4b0213e20fe, replyNumber=0, likeNumber=63, createdTime=2021-08-20, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4b0213e20fe, moduleTitle=NEJM：谷氨酰胺转胺酶2抑制剂治疗乳糜泻概念验证研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4b0213e20fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852703, encodeId=501a1852e030c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Urol：5-α还原酶抑制剂对MRI检测前列腺癌的影响, objectType=article, longId=213998, objectId=39ea21399880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39ea21399880, replyNumber=0, likeNumber=78, createdTime=2021-10-19, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39ea21399880, moduleTitle=J Urol：5-α还原酶抑制剂对MRI检测前列腺癌的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39ea21399880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852726, encodeId=b71f1852e2608, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JNCCN:肿瘤患者免疫检查点抑制剂相关口腔黏膜炎的临床特征和预后, objectType=article, longId=215394, objectId=feaa21539492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=feaa21539492, replyNumber=0, likeNumber=70, createdTime=2021-11-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=feaa21539492, moduleTitle=JNCCN:肿瘤患者免疫检查点抑制剂相关口腔黏膜炎的临床特征和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=feaa21539492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852684, encodeId=a3fb18526844e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大, objectType=article, longId=212913, objectId=5ce1212913f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ce1212913f0, replyNumber=0, likeNumber=62, createdTime=2022-02-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ce1212913f0, moduleTitle=BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ce1212913f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852658, encodeId=a9791852658e0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, objectType=article, longId=211358, objectId=b3ef2113580f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3ef2113580f, replyNumber=0, likeNumber=78, createdTime=2021-06-21, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3ef2113580f, moduleTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3ef2113580f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852755, encodeId=85521852e558f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, objectType=article, longId=217312, objectId=e46321e31264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46321e31264, replyNumber=0, likeNumber=70, createdTime=2022-08-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46321e31264, moduleTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e46321e31264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852617, encodeId=fd7f185261e61, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Oncol：PI3Kδ/CK1ε双重抑制剂Umbralisib用于治疗复发性/难治性惰性淋巴瘤, objectType=article, longId=208223, objectId=84b3208223f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b3208223f8, replyNumber=0, likeNumber=73, createdTime=2021-04-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b3208223f8, moduleTitle=J Clin Oncol：PI3Kδ/CK1ε双重抑制剂Umbralisib用于治疗复发性/难治性惰性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b3208223f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852664, encodeId=9b4f18526641a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Nat Commun：癌症疫苗+免疫检查点抑制剂，将癌症治疗效果提升3倍，已开展人体临床试验, objectType=article, longId=211592, objectId=5bde211592a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bde211592a0, replyNumber=0, likeNumber=86, createdTime=2021-12-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bde211592a0, moduleTitle=Nat Commun：癌症疫苗+免疫检查点抑制剂，将癌症治疗效果提升3倍，已开展人体临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bde211592a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

RET抑制剂TPX-0046治疗肿瘤，I/II期SWORD-1期研究已取得初步临床数据

2021-12-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性

2021-11-01

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Nat Commun：JAK抑制剂托法替尼治疗系统性红斑狼疮

2021-08-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet Oncol：IDH2抑制剂Enasidenib联合阿扎胞苷治疗IDH2突变型急性髓系白血病的疗效和安全性

2021-10-30

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

SGLT2抑制剂Forxiga获得欧盟和英国的批准，用于治疗慢性肾病

2021-09-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BMJ子刊：SGLT-2抑制剂会造成肾损伤吗？这项2万多人的队列研究告诉你答案！

2022-04-25

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后

2022-01-28

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Oncol：新型PD-L1抑制剂Toripalimab可安全有效地治疗化疗难治性转移性鼻咽癌

2021-12-31

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Br J Cancer：质子泵抑制剂PPI的使用影响结直肠癌患者的生存率

2021-08-07

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元

2021-07-30

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ESMO Open：免疫检查点抑制剂相关的心血管不良事件的真实临床数据

2021-12-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验

2021-07-14

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

NEJM：谷氨酰胺转胺酶2抑制剂治疗乳糜泻概念验证研究获得成功

2021-08-20

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Urol：5-α还原酶抑制剂对MRI检测前列腺癌的影响

2021-10-19

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JNCCN:肿瘤患者免疫检查点抑制剂相关口腔黏膜炎的临床特征和预后

2021-11-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大

2022-02-23

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验

2021-06-21

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究

2022-08-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Oncol：PI3Kδ/CK1ε双重抑制剂Umbralisib用于治疗复发性/难治性惰性淋巴瘤

2021-04-23

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Nat Commun：癌症疫苗+免疫检查点抑制剂，将癌症治疗效果提升3倍，已开展人体临床试验

2021-12-18

科室
- - 订阅+
  - 更多科室
工具
服务